Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average – Here’s What Happened

Posted by Brian Himes on Sep 23rd, 2026

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.18 and traded as high as $4.02. Galectin Therapeutics shares last traded at $3.96, with a volume of 258,375 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts have recently commented on GALT shares. Wall Street Zen upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Zacks Research upgraded shares of Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Galectin Therapeutics in a research note on Tuesday, June 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Monday, September 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Galectin Therapeutics has a consensus rating of “Hold” and an average price target of $11.00.

Check Out Our Latest Stock Report on GALT

Galectin Therapeutics Price Performance

The company’s 50 day simple moving average is $3.75 and its 200 day simple moving average is $3.19. The firm has a market cap of $266.73 million, a price-to-earnings ratio of -9.42 and a beta of 0.38.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.05). As a group, analysts forecast that Galectin Therapeutics Inc. will post -0.3 earnings per share for the current year.

Insider Buying and Selling

In other Galectin Therapeutics news, insider Khurram Jamil sold 47,467 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $5.04, for a total value of $239,233.68. Following the sale, the insider owned 2,037 shares of the company’s stock, valued at $10,266.48. This represents a 95.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Harold H. Shlevin sold 22,268 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $5.04, for a total transaction of $112,230.72. Following the completion of the transaction, the director owned 6,500 shares in the company, valued at approximately $32,760. This trade represents a 77.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 82,037 shares of company stock worth $412,974 in the last 90 days. 52.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new stake in Galectin Therapeutics in the 1st quarter valued at $413,000. Sovran Advisors LLC grew its holdings in Galectin Therapeutics by 14.1% during the 1st quarter. Sovran Advisors LLC now owns 257,830 shares of the company’s stock valued at $719,000 after purchasing an additional 31,956 shares in the last quarter. Tulsa Wealth Advisors INC purchased a new stake in Galectin Therapeutics during the 4th quarter worth $97,000. Hopwood Nicholas Hunter acquired a new position in Galectin Therapeutics in the 2nd quarter worth $322,000. Finally, Bank of New York Mellon Corp acquired a new position in Galectin Therapeutics in the 2nd quarter worth $491,000. 11.68% of the stock is owned by hedge funds and other institutional investors.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies that target galectin-3, a protein associated with fibrosis, inflammation and immune-system regulation. The company’s research is aimed at addressing serious diseases for which treatment options remain limited.

Its lead product candidate is belapectin, an investigational galectin-3 inhibitor designed to reduce fibrotic activity and potentially improve liver-related complications. Galectin Therapeutics has primarily evaluated belapectin in patients with metabolic dysfunction-associated steatohepatotic cirrhosis, formerly referred to as nonalcoholic steatohepatitis cirrhosis, including complications such as portal hypertension and esophageal varices.

Galectin Therapeutics conducts its development activities through clinical research and collaborations in the United States and other relevant markets.